Watchdogs want FDA number in DTC ads

Share this article:
Arguing that most Americans don't know about the FDA's adverse events reporting program, Consumers Union said DTC ads should include a toll-free number that patients can use to report side effects to the FDA.

The nonprofit presented the agency with a petition to that effect including 56,000 signatures. Consumer Reports, a publication of the group, released the results of a poll finding that of all respondents who had ever taken a prescription drug, 16% had experienced a serious side effect, but only 35% of all respondents were aware that side effects could be reported to FDA. 

Four out of five respondents reported seeing or hearing a drug ad within the past 30 days – nearly all on TV. Asked if ads should include reporting information, 87% said TV spots should, and 90% said print ads should do the same. 

A requirement that print ads – but not TV ads – include reporting info was included in last year's FDA Amendments Act, the group noted. Congress ordered a study on the feasibility of such a condition for TV ads as well, but the study, due at the end of March, has not been completed. 

“You can't turn on a TV today without seeing a drug ad, but those ads never mention that consumers should be reporting serious drug side effects to the FDA,” said Consumers Union campaign coordinator Liz Foley in a statement. “What better way for the FDA to let consumers know how to report serious problems with their medications than putting a toll-free number and website in all those drug ads we're bombarded by each day?”
Share this article:

Email Newsletters

More in News

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union

Rep access continues to shrink

Rep access continues to shrink

Sales reps are experiencing even more limited physician access, according to a report by Chicago consultancy ZS Associates.

Allergan touts reorg, plans to lay off 13% of workforce

Allergan touts reorg, plans to lay off 13% ...

Allergan's second-quarter earnings, and a new round of cuts, are now part of the Botox maker's record as it seeks to remain independent.